Euclidean Capital

Latest statistics and disclosures from Euclidean Capital's latest quarterly 13F-HR filing:

  • Top 5 stock holdings are SPY, INDA, FHTX, ORIC, ALEC, and represent 98.19% of Euclidean Capital's stock portfolio.
  • Added to shares of these 1 stock: SPY (+$94M).
  • Reduced shares in these 2 stocks: , Ngm Biopharmaceuticals.
  • Sold out of its positions in Ngm Biopharmaceuticals, GLD.
  • Euclidean Capital was a net buyer of stock by $3.3M.
  • Euclidean Capital has $796M in assets under management (AUM), dropping by 2.03%.
  • Central Index Key (CIK): 0001825034

Tip: Access up to 7 years of quarterly data

Positions held by Euclidean Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Portfolio Holdings for Euclidean Capital

Euclidean Capital holds 11 positions in its portfolio as reported in the June 2024 quarterly 13F filing

Company (Ticker) Portfolio Weight Valued At Change in Shares Share Count Share Price
Spdr S&p 500 Etf Tr Tr Unit (SPY) 78.4 $624M +17% 1.1M 544.22
 View chart
Ishares Tr Msci India Etf (INDA) 17.0 $135M 2.4M 55.78
 View chart
Foghorn Therapeutics (FHTX) 1.1 $9.0M 1.6M 5.75
 View chart
Oric Pharmaceuticals (ORIC) 0.9 $7.0M 989k 7.07
 View chart
Alector (ALEC) 0.7 $5.9M 1.3M 4.54
 View chart
Pmv Pharmaceuticals (PMVP) 0.5 $4.3M 2.6M 1.62
 View chart
23andme Holding Class A Com (ME) 0.5 $4.0M 10M 0.39
 View chart
Tenaya Therapeutics (TNYA) 0.4 $3.1M 1.0M 3.10
 View chart
Rapt Therapeutics (RAPT) 0.3 $2.0M 658k 3.05
 View chart
Surrozen Com New (SRZN) 0.1 $960k 88k 10.95
 View chart
Surrozen *w Exp 08/01/203 (SRZNW) 0.0 $2.8k 171k 0.02
 View chart

Past Filings by Euclidean Capital

SEC 13F filings are viewable for Euclidean Capital going back to 2020